| Literature DB >> 32489498 |
Ferda Yilmaz Inal1, Hayrettin Daskaya2, Yadigar Yilmaz3, Hasan Kocoglu1.
Abstract
INTRODUCTION: Bispectral index (BIS) monitoring provides an objective, non-invasive measurement of the level of consciousness in a sedated patient. AIM: In this prospective study, we aimed to investigate the hypothesis that risk of respiratory depression could be reduced and the desired level of sedation with minimal doses of propofol could be achieved by using BIS monitoring in endoscopic retrograde cholangiopancreatography (ERCP) procedures.Entities:
Keywords: bispectral index; endoscopic retrograde cholangiopancreatography; sedation
Year: 2020 PMID: 32489498 PMCID: PMC7233161 DOI: 10.5114/wiitm.2020.93461
Source DB: PubMed Journal: Wideochir Inne Tech Maloinwazyjne ISSN: 1895-4588 Impact factor: 1.195
Ramsay Sedation Scale
| Level | Characteristics |
|---|---|
| 1 | Patient awake, anxious, agitated, or restless |
| 2 | Patient awake, cooperative, orientated, and tranquil |
| 3 | Patient drowsy, with response to commands |
| 4 | Patient asleep, brisk response to glabella tap or loud auditory stimulus |
| 5 | Patient asleep, sluggish response to stimulus |
| 6 | Patient has no response to firm nail-bed pressure or other noxious stimuli |
Comparison of two groups in terms of demographic and clinical characteristics
| Parameter | RSS group ( | BIS group ( | |
|---|---|---|---|
| Age | 56.16 ±11.510 | 53.30 ±8.921 | 0.285 |
| Male | 16 (53.3) | 10 (33.3) | 0.192 |
| Female | 14 (46.7) | 20 (66.7) | |
| Weight | 74.53 ±14.001 | 75.03 ±14.59 | 0.893 |
| Height | 168.23 ±10.401 | 164.3 ±5.80 | 0.076 |
| ASA I | 12 (40.0) | 17 (56.7) | 0.301 |
| ASA II | 18 (60.0) | 13 (43.3) | |
| Comorbidity | 0.169 | ||
| None | 12 (40.0) | 17 (56.7) | |
| HT | 7 (23.3) | 5 (16.7) | |
| DM | 0 (0.0) | 2 (6.7) | |
| COPD | 0 (0.0) | 2 (6.7) | |
| CHD | 2 (6.7) | 0 (0.0) | |
| RA | 1 (3.3) | 0 (0.0) | |
| Thyroid disease | 1 (3.3) | 2 (6.7) | |
| HT and COPD | 5 (16.7) | 1 (3.3) | |
| HT and CHD | 1 (3.3) | 0 (0.0) | |
| DM and thyroid disease | 1 (3.3) | 1 (3.3) | |
| Indications | 0.154 | ||
| Choledocholithiasis | 10 (33) | 14 (36) | |
| Biliary leaks | 7 (23) | 2 (6) | |
| Biliary stenosis | 6 (20) | 6 (20) | |
| Stent exchange | 2 (6) | 3 (10) | |
| Stent extraction | 2 (6) | 2 (6) | |
| Others | 3 (10) | 3 (10) |
£Mann-Whitney U test
independent samples t-test
Fisher-Freeman-Halton test.
HT – hypertension, DM – diabetes mellitus, COPD – chronic obstructive pulmonary disease, CHD – coronary heart disease, RA – rheumatoid arthritis.
Figure 1Comparison of SpO2 values
Number of drops in SpO2 (< 90%) and interventions related to it*
| Parametr | RSS group ( | BIS group ( | |
|---|---|---|---|
| Number of drops in SpO2
| |||
| 0 time | 10 (33.3) | 19 (63.3) | 0.010 |
| 1 time | 9 (30.0) | 6 (20.0) | 0.402 |
| 2 times | 4 (13.3) | 5 (16.7) | 0.816 |
| 3 times | 7 (23.3) | 0 (0) | 0,010 |
| Increasing nasal O2 > 2 l/min, | 18 (60.0) | 8 (26.6) | 0.001 |
| Jaw lifting, | 1 (3.3) | 0 (0.0) | 0.321 |
Fisher-Freeman-Halton test was used.
Figure 2Comparison of respiratory rates
Duration of anaesthesia, recovery time, NRS values, total amount of propofol, additional doses of propofol bolus, and endoscopist and patient satisfaction
| Paramater | RSS group ( | BIS group ( | |
|---|---|---|---|
| Duration of anaesthesia | 27.23 ±14.488 | 24.33 ±11.80 | 0.399 |
| Recovery time | 10.83 ±6.308 | 9.16 ±5.583 | 0.283 |
| Total amount of propofol | 216.0 ±124.67 | 207.0 ±60.41 | 0.724 |
| Additional doses of propofol | 5.10 ±7.336 | 4.03 ±4.055 | 0.489 |
| Endoscopist satisfaction | 3.50 ±0.682 | 3.76 ±0.430 | 0.092 |
| Patient satisfaction | 3.93 ±0.253 | 3.90 ±0.305 | 0.643 |
Mann-Whitney U test
independent samples t-test.